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1. Introduction
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes
is a series of Editorials that is published on a biannual basis by the Editorial Board of the Medicinal
Chemistry section of the journal Molecules. In these Editorials, we highlight in brief reports (of about
one hundred words) a number of recently published articles that describe crucial findings, such as the
discovery of novel drug targets and mechanisms of action or novel classes of drugs, which may inspire
future medicinal chemistry endeavors devoted to addressing prime unmet medical needs.
2. Siderophores, Did You Say Siderophores?
Highlighted by Jean Jacques Vanden Eynde
Ferric ions (Fe3 +) play a vital role in many cellular processes but their poor solubility under
biological conditions hampers their transmembrane movements. The situation is facilitated by chelating
the ion, and many microorganisms are capable of secreting such chelates, which are called siderophores
(from the ancient Greek language: “iron carrier”). Designing siderophore mimetics (Figure 1) is
expected to combat bacteria and fungi by introducing either toxic metals or antibiotics into the
organism. This strategy has been recently exploited by the team of P. Sonnet [1] in order to evaluate the
antipseudomonal activities and cytotoxicity of conjugates bearing a piperazine moiety and a catechol
(1) or an hydroxypyridone (2) chelating group.
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3. A Combined Neuroprotective Approach for Dementia
Highlighted by Arduino A. Mangoni
The identification of new, effective drugs for the treatment of dementia remains
challenging. Targeting multiple pathways involved in the onset and the progression of the
disease might increase the success rate of drug discovery and development programs [2].
Scheiner et al. report the synthesis of a series of hybrid molecules that are based
on the cholinesterase inhibitor tacrine and a benzimidazole-based human cannabinoid
receptor subtype 2 agonist [3]. The hybrids exhibited significant inhibitory effects towards
cholinester se activity and Aβ40 and Aβ42 aggregatio , d concomitant partial agonist
activi y towards the human cannabinoid receptor sub pe 2. Furthermore, the compound
2-(4-ethoxybenzyl)-1-isop ntyl-N-(2-((2-((1,2,3,4-tetr hydroa ridin-9-yl)amino)ethyl)disulfaneyl)ethyl)
-1H-benzo[d]imi azole-5-carboxamid exert d sign ficant, concentration-dep ndent, neuroprotective
effects in murine hipp campal neurons and prevented Aβ25-35-induced sh rt- and long-term memory
impairment in mice [3]. Notably, animal studies did not show any evidence of hepatotoxicity, a
common complication during treatment with tacrine [4]. Pending further in vivo investigations, the
results of this study suggest that agents with dual cholinesterase inhibition and human cannabinoid
receptor subtype 2 activation might represent a promising therapeutic strategy for dementia.
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4. Prodrug Strategy for Multiple Charged Drugs
Highlighted by Jarkko Rautio
2-(Phosphonomethyl)pentanedioic acid (2-PMPA), which is a potent (IC50 = 300 pM) and selective
inhibitor of glutamate carboxypeptidase II, has demonstrated preclinical efficacy in various neurological
and psychiatric disease models as well as in inflammatory bowel disease and cancer models. However,
due to its four acidic functionalities that are ionized at physiological pH it suffers from poor oral
bioavailability (<1%) and has not been clinically developed. Masking two to four of the acidic groups
using (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL), a cyclic carbonate promoiety significantly
improved lipophilicity (clogP) compared to that of 2-PMPA. All prodrugs delivered significantly higher
2-PMPA plasma concentrations in a single time-point screening study in mice. The best prodrug
consisting of four ODOL promoieties demonstrated an 80-fold enhancement in exposure versus oral
2-PMPA in an extended time-course pharmacokinetic study in mice with an absolute oral bioavailability
of 50%. This prodrug also delivered a 44-fold enhanced 2-PMPA plasma exposure in further studies
in dogs. Results demonstrate the applicability of the FDA approved ODOL promoiety in multiple
charged drugs [5].
5. A SOX9-Derived Peptide Inhibits the Growth of Colorectal Cancer Tumors
Highlighted by Jérôme Leprince
The oncogenic Wnt/β-catenin signaling pathway is constitutively activated in all inherited, and in
80% sporadic, colorectal cancers. This activation results in an accumulation of non-phosphorylated
β-catenin in the nucleus of tumor cells, which activates the T-cell transcription factor leading to the
expression of pro-oncogenic Wnt/β-catenin signaling target genes, such as c-Myc. Recently, Blache et al.
reported that doxycycline-evoked expression of S9pep, a 21-residue long fragment of the transcription
factor SOX9, inhibits Wnt/β-catenin signaling and c-Myc expression by β-catenin relocation into
the cytoplasm [6]. A syngenic graft of S9pep-expressing colorectal cancer cells in mice reduces
tumor growth in comparison to non-expressing tumor cells. These results pave the way toward the
development of promising S9pep analogues to tackle colorectal cancers.
6. Ustekinumab, an Anti-IL-12/23 p40 Monoclonal Antibody, as a Molecularly-Targeted Therapy
for the Treatment of Crohn’s Disease
Highlighted by Yasu-Taka Azuma
Molecularly-targeted therapy is a therapy that treats a specific molecule by targeting it and
controlling its function. IL-12 is a heterodimer consisting of the p40 and p35 subunits. On the
other hand, IL-23 is a heterodimer in which the p19 subunit is bound to the same p40 subunit
as IL-12. IL-12 induces Th1 cell differentiation, whereas IL-23 induces Th17 cell differentiation.
By suppressing p40, a common subunit, it is possible to suppress both Th1 and Th17. In particular,
p40 is taken up as a therapeutic target molecule for Crohn’s disease [7]. Li et al. reported the effect
of ustekinumab, a monoclonal antibody against p40, on the microscopic manifestations of Crohn’s
disease [8]. Improvement was observed 8 weeks after administration of this antibody. Thereafter,
observation was made up to the 44th week. Improvement was observed even at 12 week intervals, and
further improvement was observed at 8 week intervals over the 12 week intervals. This antibody has
further expanded the options for treating Crohn’s disease.
7. A Stab in the Back of TB: Recovering Mycobacterium tuberculosis Fumarate Hydratase Through
a Non-Conserved Allosteric Site
Highlighted by Alfonso T. García-Sosa
Despite a long history, an estimated fourth of the world’s population is infected withM. tuberculosis.
It kills over one million people each year and resistance to current therapeutics is becoming widely
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spread and transmissible. The bacteria’s fumarate hydratase enzyme is highly conserved with the
human homologue. Promising work [9] succeeded in targeting a non-conserved allosteric site on
the highly-conserved (with conserved active site) enzyme, which makes the compounds all the more
interesting due to the possibility of a higher selectivity index against the human enzyme, as well as
being able to permeate the mycobacterial cell wall.
Whitehouse et al. [9] recovered a previous lead compound with a unique dimeric, induced-fit
binding mode and MIC of 250µM by SAR on head and tail functional groups to achieve new compounds
with activity against both fumarate hydratase and M. tuberculosis H37Rv bacteria.
The compound with the best MIC value was N-(5-(azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-
(benzofuran-3-yl)acetamide; and that with the best IC50 value was N-(5-(azocan-1-ylsulfonyl)-2-meth
oxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide, thus rescuing both a target and a
compound series.
8. New Hopes for 3rd Generation Castration Resistant Prostate Cancer Drugs: Arv7 Splice Variant
Binders
Highlighted by Christopher Hulme
Androgen receptor (AR) reactivation is thought to be the key mechanism that drives
castration-resistant prostate cancer (CRPC) resistance to second generation antiandrogens, like
enzalutamide, which partly involves the generation of AR splice variants lacking a ligand binding
domain (LBD). As such, a dominant splice variant is Arv7, and high content screening, followed
by optimization delivered the small molecule JJ-450, (4-(5-chloro-2-methylphenyl)piperazin-1-yl)
((1RS,2SR)-2-(4-fluorophenyl)cyclopropyl)methanone, which inhibits Arv7 transcriptional activity and
its target gene expression. Moreover, the molecule inhibits the growth of CRPC tumor xenografts,
including ARv7-expressing 22Rv1. Taken together, the results are highly suggestive that JJ-450 is a new
class of AR antagonist with potential as a third generation therapeutic for CRPC, which critically is
effective in animals resistant to the LBD binder enzalutamide [10].
9. Multi-Target Drugs for Rheumatoid Arthritis Management
Highlighted by Josef Jampilek
Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease leading to chronic
inflammation of synovial tissue with subsequent disintegration of articular cartilage and bone.
Common symptoms are joint pain, stiffness, swelling, and deformities. Inflammation leads to
respiratory and cardiovascular diseases increasing RA mortality. Pharmacological treatment to
alleviate inflammation and reduce the progression of structural damage frequently consists of the
administration of nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, methotrexate, and
biological drugs. Despite the progress in treatment, patients still do not have a sufficient response
to therapy or suffer severe side effects [11]. The multi-target approach in drug design leads to
the preparation of hybrids of NSAIDs and carbon anhydrase inhibitors (CAIs) [12,13]. Supuran’s
research team designed molecules formed by an ester bridge linking NSAIDs with coumarin type CAI.
Adducts of 6-/7-hydroxycoumarins with ketoprofen inhibited CA IV, IX, XII isoforms in the nanomolar
range and COX-1/COX-2. (±)-2-[(2-Oxo-2H-chromen-6-yl)oxy]ethyl 2-(3-benzoylphenyl)propanoate
demonstrated the most promising antihyperalgesic effect in the in vivo rat RA model. These NSAID-CAI
hybrids are cleaved in plasma depending on the NSAID used but are easier than their pattern amide
isosteres [14].
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10. Sodium Oligomannate—A Novel Drug for the Treatment of Mild to Moderate
Alzheimer’s Disease
Highlighted by Rafik Karaman
Dementia is characterized by a decline in memory, language and other thinking skills that affect
the ability of a person to execute daily activities. According to WHO, the number of people affected by
dementia is more than 50 million worldwide, Alzheimer’s disease (AD) is the most common form of
dementia and accounts for 50 to 60% of cases. Therefore, drugs having the ability to slow down or
prevent all forms of dementia are crucially needed.
In a 9-month phase 3 clinical trial involving 818 patients, the drug oligomannate showed improved
cognitive function after just 4 weeks in patients with mild to moderate AD. Oligomannate was
not found to target β-amyloid proteins in the brain but instead, it alters the connection between
the microbiome and the brain. Based on the results that oligomannate suppresses gut dysbiosis
and phenylalanine/isoleucine accumulation, harnesses neuroinflammation and reverses cognition
impairment, it was concluded that oligomannate has the potential to inhibit the progression of AD.
Researchers are now convinced that gut bacteria may be involved in many neurological disorders
including AD. The oligomannate discovery opens the door widely to address many other diseases via
targeting the microbiome [15].
11. New Strategies to Reduce Off-Target Toxicity and Identify True Targets to Improve
Clinical Successes
Highlighted by Wei Li
The chance of a new drug progressing from its entrance in clinical trials to FDA approval is
only 3%. The most common causes for failures are inadequate efficacy and/or dose-limiting toxicities,
but the lack of more rigorous validation of the drug target plays a significant role, as demonstrated
by a recent study [16]. The authors analyzed several drugs and drug targets that are currently in
clinical trials and found that some targets are actually non-essential for cancer cell growth, and that
the anticancer effects for certain drugs actually result from unintended off-target effects. The key to
these studies is to use more precise CRISPR-Cas9 techniques instead of traditional RNA interference
or small-molecule inhibitors. They further demonstrated that the true target for the drug OTS964 is
CDK11, not the reported PBK. Given the importance of identifying reliable biomarkers for patient
selection, a more stringent genetic validation of the drug target in preclinical settings is very critical
to decrease the high failure rate in drug development programs and significantly benefit both drug
developers and cancer patients.
12. Crossing a Formidable Barrier: Seven Molecular Descriptors for BBB Permeability Prediction
Highlighted by Paula A. C. Gomes
After the advent of combinatorial synthesis and high-throughput screening for fast selection of
vast numbers of hits, it was perceived that many such hits did not possess adequate pharmacokinetics.
This led to the “drug-likeness” concept, where physicochemical descriptors are used to predict how
“druggable” a compound is, pioneered by Lipinsky with his “Rule of Five” proposed in 1997 [17].
Since then, diverse algorithms have been advanced to estimate the bioavailability of a compound [18],
but tools to predict the ability to cross the blood–brain barrier (BBB) remain scarce. Anticipation of
such ability is crucial for any drug candidate, as while some drugs have to cross the BBB to exert their
action, others should not, to avoid unwanted effects. Hence, the “BBB Score”, recently proposed by
Weaver and co-workers [19] is highly relevant for medicinal chemists. The “BBB score” introduces an
algorithm to estimate the BBB permeation ability based on molecular weight, topological polar surface
area, pKa, and the number of aromatic rings, heavy atoms, hydrogen bond donors, and hydrogen bond
acceptors, and is a valuable add-on to current tools for drug design.
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13. Design, Synthesis and Biological Evaluation of Second-Generation NLRP3
Inflammasome Inhibitors
Highlighted by Dimitra Hadjipavlou-Litina
Inflammasomes are multimeric protein complexes that assemble in the cytosol after sensing
pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs)
and are linked to a variety of autoinflammatory and autoimmune diseases, including neurodegenerative
diseases and metabolic disorders. Thus, NLRP3 inflammasomes have been recently described as
an attractive drug target for neurodegenerative disorders. Several small-molecule inhibitors have
been recently reported to block the NLRP3 inflammasome pathways. Zhang et al. [20] suggested
earlier that sulfonamide analogues like JC124 can directly interfere with the formation of the NLRP3
inflammasome complex. Further development of analogues based on this template with improved
potency and drug-like properties was presented, with the design of HL16 [21]. However, HL16 showed
no selectivity. Improvement of the structure (Figure 2) with replacement of the 2-OCH3 group and
the presence of a heteroaromatic acetamide provided analogues with improved potency, leading to a
new selective lead, YQ128, with an IC50 of 0.30 µM. In vivo models confirmed its brain penetration.
Pharmacokinetic studies at 20 mg/kg in rats indicated extensive systemic clearance, tissue distribution
with a half-life of 6.6 h, low oral bioavailability and no efflux transport.
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14. Sphingosine-1-Phosphate Signaling Is Involved in Cigarette Smoke-Induced
Airway Pathology
Highlighted by Raffaele Capasso
The most important risk factor for COPD is cigarette smoking. COPD is characterized by
progressive obstruction of airflow, not fully reversible, caused by deleterious particles or gases in lung
parenchyma. There are currently no specific COPD treatments and smoking cessation remains the
most effective therapeutic intervention. Recently De Cunto et al. demonstrated the involvement of
sphingosine-1-phosphate (S1P) signalling in the progression of airway dysfunction associated with
emphysematous lesions following chronic exposure to cigarette smoke [22]. In their experimental
setting cigarette smoke triggers a lung inflammation [23], that slowly develops and promotes the airway
structural changes responsible for the cholinergic hyper-responsiveness of both lower (early response)
and upper (later response) airways from month 9 onwards. The authors support the hypothesis of an
active role of Sph-K/S1P signalling pathway in the altered cholinergic control of airway function [24]
triggered by cigarette smoke. Thus, the S1P pathway represents a feasible therapeutic target in airway
hyperresponsiveness associated with emphyse a and, particularly in smokers, with both asthma and
COPD (ACOS patients), a patient category more exposed to the disease progression and mortality.
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15. New Class of Antifungals against Aspergillus fumigatus
Highlighted by Athina Geronikaki
In the last decades, fungal infections have been a growing problem worldwide causing morbidity
and mortality. Their treatment still remains an important and challenging problem due to emerging
infectious diseases and the increasing number of multi-drug resistant pathogens. One of the most
widespread fungal pathogens is Aspergillus fumigatus, responsible for serious and often deadly invasive
infections especially in the case of immunocompromised patients. Among antifungals, azoles are the
most widely clinically used class. Triazoles, second generation, are today the first-line antifungals in
the treatment of aspergillosis.
By combination of in silico techniques and methodologies Zoumpoulakis et al. developed new
scaffolds endowed with antifungal activity against A. fumigatus [25]. After pharmacophore filtering
followed by molecular docking, eight compounds were selected and evaluated for antifungal activity.
Three of them displayed the highest activity. Their mechanism of action against CYP51 was studied
using molecular dynamic simulations. All these compounds exhibited a common binding mode.
The results revealed that these three compounds, being different from classical azoles, are the most
promising and could be used as lead compounds for further optimization.
16. Conditional Oligonucleotide Aptamers as a Powerful Tool for Targeted Cancer Therapy
Highlighted by Laura Cerchia
Oligonucleotide aptamers, which interact tightly with their targets by recognizing a specific
three-dimensional structure, may rival or complement protein antibodies as recognition elements in
diagnosis and therapy [26]. The easy and reproducible manufacturing of aptamers combined with
their composition that supports a plethora of chemical modifications allowing different conjugation
chemistries renders them ideal molecular recognition probes for setting advanced anti-cancer strategies.
Recently, Tan’s group, in order to ameliorate the aptamers performance toward an efficacious targeted
cancer therapy, developed a strategy to confine the aptamer’s action solely to cancer cells while sparing
normal cells, a crucial need when the aptamer’s target is preferentially but not exclusively expressed in
tumors [27]. They conjugated the aptamer with PEG5000-azobenzene-NHS, which acts as a caging
moiety preventing aptamer-target recognition. When the conjugate reaches the site of the tumor, the
hypoxic microenvironment triggers a self-immolative reaction that releases the aptamer competent for
binding to its cell surface target. This conditional activation strategy overcoming the potential for the
on-target off-tumor effect of aptamers, as well as antibodies, opens a new and powerful avenue for
targeted cancer therapy.
17. DNA-Based Nanostructures Open the Way to the Discovery of ‘Novel’ Antivirals with
Appropriate 3-D Arrangements and Binding Properties
Highlighted by Jean-Marc Sabatier
In the search for drugs against the Dengue flavivirus, a new approach has been described by
Kwon and collaborators [28], which is based on designer DNA nanostructures with some structural
characteristics allowing the appropriate spacing and 3-D positioning of the binding sites. They produced
a star-shaped DNA scaffold with molecular beacon-like motifs to expose aptamers that strongly
recognized the envelope protein domain III clusters located at the viral surface. This compound was a
potent antiviral (and binding sensor). Although the design of such bioactive DNA-based multivalent
antivirals might be complex, this work opens the way to the development of a new generation of
antimicrobial candidates.
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18. Towards the Synthesis of Highly Effective Treatment of Autoimmune Diseases through
Inhibition of Tyrosine Kinase 2
Highlighted by Rino Ragno
BMS-986165 is a new allosteric and selective inhibitor of tyrosine kinase 2 (TYK2) recently described
by Wrobleski et al. [29]. Different from other Janus family of kinase (JAK) inhibitors, BMS-986165 was
demonstrated to be able to allosterically and highly selectively bind the TYK2 pseudokinase or “Janus
Homology 2” (JH2) domain. Crystal structure investigation (Figure 3) revealed the unique molecular
BMS-986165 binding mode into JH2 domain, revealing the allosteric inhibition. The report is an example
of a very important medicinal chemistry result through hit to lead and lead optimization in the very
challenging objective to seek for ATP-based kinase selective inhibition across the kinome and especially
within the JAK family. BMS-986165 was discovered by means of application of modern approaches
and is currently under clinical development as potential treatment for psoriasis, Crohn’s disease and
systemic lupus erythematosus. Interestingly, the same group reported a subsequent research article in
which BMS-986165 analogues [30] have been deeply investigated as selective allosteric TYK2 inhibitors
through in vitro and in vivo experiments, thus giving a strong proof of concept of their achievements.Molecules 2019, 24, x FOR PEER REVIEW 9 of 23 
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19. A Bayesian Machine Learning Model Developed using Diverse Data Types: A Promising
Approach in the Target-Fishing Field
Highlighted by Tiziano Tuccinardi
Currently, target-fishing approaches are important strategies in medicinal chemistry for identifying
the most probable targets of a small molecule. A successful approach would make it possible to
clarify the mechanism of action of therapeutically interesting compounds for which the target is still
unknown. Furthermore, target-fishing would be useful to predict adverse effects of drug candidates
and would also accelerate drug repurposing campaigns. Elemento and co-workers developed BANDIT,
a Bayesian ANalysis to determine Drug Interaction Targets, that integrates more than 20,000,000
data points from drug efficacies, post-treatment transcriptional responses, drug structures, reported
adverse effects, bioassay results and known targets. As a measurement of the reliability of the model,
the authors were able to replicate shared-target relationships, individual drug–target relationships
and known mechanisms of action within a predefined test set. Finally, the reliability of the model
was experimentally evaluated by confirming new suggested biological activities by using different
bioassays and model systems [31]. Given the interesting results obtained, BANDIT represents an
important tool that should encourage the development of new computational target-fishing platforms.
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20. First-in-Class Clinical O-GlcNAcase Inhibitors as a Therapeutic Agent for the Treatment
of Tauopathies
Highlighted by Andrea Trabocchi
Intracellular tau aggregates are a common outcome in a number of neurodegenerative disorders
referred to as tauopathies, which are associated with synaptic loss and neuronal death. O-GlcNAcylation
in mammalian cells is regulated by the two enzymes glycosyltransferase O-GlcNAc transferase and
glycoside hydrolase O-GlcNAcase. O-GlcNAcylation of tau regulates its phosphorylation state, as lower
tau phosphorylation is maintained by increased O-GlcNAc modification. Thus, the pharmacological
blockade of O-GlcNAcase has been recognized as a therapeutic approach to prevent neurodegeneration
brought on by pathological tau by reducing the formation of pathogenic tau aggregates. MK-8719 is a
small molecule developed by Merck as an inhibitor of the O-GlcNAcase enzyme, identified through
medicinal chemistry and pharmacological studies of a set of molecules based on a previous lead
candidate in view of reducing the polar surface area to align the desired drug-like properties [32].
It has been reported that MK-8719 (Figure 4) shows good pharmacokinetic properties with excellent
brain penetration, and a robust and sustained pharmacodynamic response, allowing for its selection as
a development candidate for first-in-class human phase I clinical trials for the treatment of tauopathies.
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Highlighted by Jean-Yves Winum
The membrane bound carbonic anhydrase isoforms hCA IX and hCA XII are considered as
therapeutic targets for hypoxic tumors s both of these enzymes are associated with cancer progression,
m t stasis, and impaired therapeutic response. The dev lopment of new and effective inhibitors is
driven by the specific targeting of hCA IX/hCA XII over the ubiquitous cyt solic off-target isoforms hCA
I and hCA II [33]. Bua and colleagues investigated a new cyclic ureidosulfonamide chemotype based
on a 2H-benzo[e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxide scaff ld, and resulting from the combination
design of the structure of saccharin and acesulfame K [2]. Many derivatives sh wed enhanced
inhibitory activity a d selectivity against hCA IX/hCA XII isoforms. In vitro evalu tion of anticancer
activity revealed an en anced growth inhibition with a low micromolar IC50 against HCT-116 cells
under hypoxic conditions. The effect on apoptosis markers in HTC-116 cell lines as a increased level
of pro-apoptotic protein expression (Bax, caspase-3 and -9 a pf53) upon treatment with this family
of inhibitors [34]. This study paves the way for the drug design and development of new potential
candidate dr gs targeting tumor-associated carbonic anhydrase isoforms.
22. Expanding the Human Proteome with Functionalized Enantiomeric Probes
Highlighted by F. Javier Luque
Assessing the ‘ligandability’ of proteins is important to explore the ability of the human proteome
to bind small molecules, to interrogate the functional role of proteins, and eventually to validate the
target druggability in drug discovery. In the search f methodo gical approach that nables a
gl bal assessment of small-molecule/protein interac ions i cells, the authors d velope functiona ized
fragmen probes, which include different fragments coupled to photoreactive and bioorthogon l
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reporter groups, enabling the mapping of >2000 reversible fragment-protein interactions [35]. In this
work [36], Parker, Cravatt and coworkers report the next-generation set of functionalized fragment
probes, which consist of fragment pairs differing only in absolute stereochemistry. They are intended to
provide stronger evidence for the formation of specific stereoselective interactions with proteins in cells.
Indeed, using a set of eight pairs of enantiomeric probes, >170 small-molecule/protein interactions
were found, including the binding to functionally relevant sites. The disclosure of these stereoselective
interactions will be valuable to develop more potent and selective compounds against specific proteins
in the cell, leading to more efficient chemical probes and drugs.
23. Targeting IL-11 to Halt and Reverse Fibrosis and Inflammation in the Lung
Highlighted by Katalin Prokai-Tatrai
Patients suffering from incurable idiopathic pulmonary fibrosis (IPF) have abnormal levels of
interleukin 11 (IL-11). This protein stimulates fibroblast activation, and therefore, is a critical contributor
to fibrosis and inflammation across organs, including the lung. Excessive scarring around the air sacs in
the lung eventually leads to respiratory failure and death. Current anti-inflammatory and antifibrotic
therapies cannot stop IPF, whose pathophysiology remains to be fully understood. Recently, Ng et al.
reported their exciting findings on IL-11 as a therapeutic target for IPF [37]. In vitro mechanistic studies
in primary human lung fibroblast cultures were conducted to gain insight into the signaling pathways
important for IL-11-driven fibrosis, while in vivo studies used the bleomycin model of pulmonary
fibrosis in mice. The research team showed through this model that a neutralizing IL-11 antibody not
only diminished lung inflammation but also reversed existing tissue scarring in the animals’ lungs. It is
anticipated that IL-11 inhibition using this type of antibody would be devoid of detrimental side effects
associated with available antifibrotic therapies, altogether raising hope that the authors’ findings in the
mouse model of pulmonary fibrosis can be translated to the curative treatment of IPF patients.
24. Unique Tetrapeptides from a Penicillium Fungus as Biased Analgesics Targeting the
µ-Opioid Receptor
Highlighted by Mariana Spetea
The µ-opioid receptor (MOPr) agonists are the most effective analgesics, but their usefulness
is limited by serious adverse effects. Medical use and misuse of opioids resulted in a huge rise in
opioid-related overdose deaths in the past years. Biased agonism at the MOPr has gained increased
importance for opioid drug discovery, where G protein-biased MOPr agonists may deliver analgesia
with fewer side effects [38]. Further, compounds derived from natural resources are valuable leads for
new drug candidates. Both strategies have been combined by Dekan et al. [39], where discovery of
three unusual tetrapeptides with a unique stereochemical arrangement of hydrophobic amino acids
from an Australian estuarine isolate of Penicillium species is presented. The SAR study led to the
design of bilorphin (Figure 5), a potent and selective G protein-biased MOPr agonist. Bilorphin adopts
a distinct conformational shape and intermolecular interactions in molecular dynamics simulations.
Through the addition of a simple sugar moiety, bilactorphin was generated (Figure 5), as an orally
active and effective analgesic in vivo. These findings provide significant knowledge for creating novel
pain therapeutics based on microbes, deserving further scientific attention.
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25. Optimized Peptidic Michael Acceptors for the Treatment of Human African Trypanosomiasis
Highlighted by Michael Gütschow
Rhodesain, a catheps n L-like ysteine p otease of Trypanosoma brucei hodesiense, represents a
promising target for the development of new drugs against the protozoan disease human African
trypanosomiasis (HAT), well-known as sleeping sickness. Roberta Ettari at the University of Messina,
Italy, and co-workers synthesized a new series of peptidyl vinyl ketones employing a cross-metathesis
reaction as key step. The compounds were kinetically characterized to be potent inactivators of
rhodesain [40].
One of the lead compounds (Figure 6) showed an impressive binding affinity for rhodesain (Ki = 0.6
pM), a strong inhibitory effectiveness (k2nd = kinac/Ki = 1,785,000 M−1s−1), sufficient selectivity towards
human cathepsin L, the closest human homolog, as well as good antiparasitic activity as determined
using an ATP-monitoring system based on firefly luciferase (EC50 = 0.67 µM). Such optimized
peptidomimetics certainly represent promising lead compounds for the discovery of new drugs to
treat HAT.
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As the safety profile, adverse effects and pharmacological activity of medicinal products with
marketing authorization is known, r purposing has a bri ht future, especially for search of new
antimicrobi ls [41]. Cl stridioides difficile infections (CDI) are increasing in mortality and morbidity
in hospital settings, and this opportun stic bacterial pathogen presents a typ cal outcome of the
complex in eractio between host-defense and microbial virul nce accord ng to he damage-response
framework [42]. The w rk of Hutton et al. [43] demonstrates that auranofin, a drug used orally for
rheumatoid arthritis treatment, causes a growth inhibition of veget tive cells, sporulation and toxin
producti n of C. difficil in vitro. More importantly, the authors also showed that auranofin could be
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the in vitro and in vivo data, it could be concluded that auranofin is an important candidate for its
repurposing for a new indication.
27. A New Efficient Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptor. New
Hope for the Treatment of Patients with Mild to Moderate Alzheimer’s Disease
Highlighed by Catherine Guillou
Modulation of α7 nicotinic acetylcholine receptors (nAChRs) by positive allosteric modulators
(PAM) is a promising therapeutic approach for the treatment of Alzheimer’s disease (AD), schizophrenia
and attention deficit hyperactivity disorder. Researchers from Lupin LTD have identified a novel PAM
of α7 nAChR, a thiophenephenylsulfonamide that showed good in vitro potency, with excellent brain
penetration and residence time [44]. This compound reverses the cognitive deficits in episodic/working
memory in both time-delay and scopolamine-induced amnesia. Additionally, it showed an excellent
safety profile in phase 1 and is being evaluated in monotherapy in patients with mild to moderate AD.
28. CD9 Is a Marker and a Potential Therapeutic Target for Pancreatic Ductal Adenocarcinoma
Tumor-Initiating Cells
Highlighed by M. Helena Vasconcelos
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive cancer with increasing incidence;
it is difficult to treat and has a poor prognosis. PDAC has high cellular heterogeneity and a high
degree of plasticity. The tumor initiating cells or cancer stem cells (CSC) are highly proliferative,
have ability to promote metastatic dissemination, and are drug resistant and capable of originating
cellular heterogeneity. Nonetheless, so far their identification and targeting has been difficult due to
the lack of specific markers. The recent publication by Wang et al. [45] identified the tetraspanin CD9
as a CSC marker for PDAC. Interestingly, CD9 had previously been identified as a CSC marker in
glioblastoma [46] and B-cell acute lymphoblastic leukemia [47]. Remarkably, in this study CD9 was
also found to enhance glutamine uptake into PDAC cells, allowing altered tumor cell metabolism and
supporting PDAC development. Thus, this function of CD9, together with its localization at the cell
membrane, makes it an attractive target for therapeutic intervention in PDAC.
29. The FDA-Approved Drug Neratinib Protects Pancreatic Beta Cells in Diabetes
Highlighted by George Kokotos
The discovery of novel agents that may block β-cell apoptosis and at the same time restore
β-cell function is of great importance to fight diabetes. Ardestani et al. recently demonstrated that
neratinib (Figure 7), an FDA-approved drug targeting HER2/EGFR dual kinases, is a potent mammalian
sterile 20-like kinase 1 (MST1) inhibitor, which improves β-cell survival under multiple diabetogenic
conditions in human islets and INS-1E cells [48]. Five years ago, it was reported that MST1 is a key
regulator of pancreatic β-cell death and dysfunction [49]. The present work shows that neratinib is a
previously unrecognized inhibitor of MST1, which is able to attenuate hyperglycemia and improve
β-cell function, survival and β-cell mass in type 1 (streptozotocin) and type 2 (obese Leprdb/db)
diabetic mouse models. Thus, it represents a potential β-cell-protective drug.
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30. Human Asparagine Synthetase is a Promising Anticancer Drug Target
Highlighted by Giulio Rastelli
Asparagine synthetase (ASNS) is an enzyme that catalyzes the ATP-dependent biosynthesis of
L-asparagine in cells. Several evidences indicate that ASNS is involved in several types of cancers, but
little information is available about this potential drug target. The study by Zhu et al. [50] reports an
exemplary approach integrating proteomics, crystallography, computational modelling and molecular
biology to clarify important mechanistic and structural information about this target. First, the authors
demonstrated that one selected methylsulfoximine inhibitor exhibits excellent selectivity in HCT-116
cell lysates, with almost no off-target binding. Then, they determined the first high-resolution crystal
structure of human ASNS, which was used to perform docking, molecular dynamics and free-energy
perturbation studies of enzyme–ligand complexes. The resulting binding modes were used to select
site-directed point mutations to map and probe the ligand binding site. Overall, this study sets the
basis for the design and discovery of a second generation of potent, selective and more drug-like
inhibitors of human ASNS to be developed as drugs against metastasis.
31. Visible Light Photoactivatable Prodrugs: Design of the Platinum Magic Bullet
Highlighted by Maria Emília de Sousa
Photoactivatable molecules are considered in strategic advances in medicinal chemistry [51].
The concept of light liberating a photolabile protecting group has been used in photodynamic therapy
or in prodrugs to control the activity of a bioactive compound in a more precise temporal release for
specific effects. Zhigang Wang et al. [52] reported the design of chemotherapeutic “magic bullets” that
can be controllably activated by red light, allowing high penetration. The group developed phorbiplatin
a stable mutual prodrug of oxaliplatin, a first-line clinical antineoplastic, and pyropheophorbide (PPA), a
photo-absorber that, acting as carrier, has also the function of photosensitizer. A unique photoreduction
mechanism is proposed to quickly and efficiently activate oxaliplatin in a spatial and temporal fashion.
Phorbiplatin is able to kill tumor cells much more efficiently than the mixture of the parent drug with
PPA in a mouse tumor model.
A spatial and temporal breakthrough was made due to the first arsenic-based magic bullet to
bring light into the commemorations of the 150th anniversary of the Periodic Table (Figure 8).
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32. Allosteric Modulators of Cannabinoid Receptor 1: Developing Compounds for Improved
Functional Diversity
Highlighted by Clementina Manera
CB1 cannabinoid r ceptor (CB1R) is well-known as a target for the treatment of several pathologies.
However, its direct modulation by agonists or antagonists/inverse agonists has been associated with
undesirable effects on the central nervous system (CNS), thus limiting the clinical development of
such agents. Allosteric modulators (AMs) represent a promising approach to achieving the potential
therapeutic benefits of the orthosteric CB1R ligands, while avoiding their side-effects. In particular,
agonist-positive allosteric modulators (ago-PAMs) that increase potency and/or efficacy of orthosteric
agonists, as well as displaying intrinsic efficacy, may be suitable for treating diseases whose etiology
involves severe loss of endogenous neurotransmitters.
Recently, the application of fluorine- and nitrogen-walk approaches to the 2-phenylindole scaffold
permitted the identification of two key compounds with high ago-PAM activity, good lipophilicity and
drug-like physicochemical properties [53]. Both compounds also exhibited good in vivo potency in a
preclinical inflammatory pain model with long-lasting action without adverse cannabimimetic effects
and therefore they could be worth investigating in select CNS disorders. Finally, the observed SAR
trend was accounted for by using a recently developed computational model for the CB1R allosteric
agonism [54].
33. Inhibition of Trypanothione Reductase by 4,15-iso-Atriplicolide Tiglate: Mode of Inhibition
and Structural Requirements
Highlighted by Sandra Gemma
Natural products are an invaluable source of new drugs and lead compounds against a plethora
of diseases, with enormous contribution to the discovery of antibacterial and antiparasitic drugs.
Sesquiterpene lactones (STLs) have been demonstrated to have potent and, in many instances, selective
toxicity against protozoan parasites, the etiological agents of several neglected tropical diseases (NTDs).
Recently, furanoheliangolide-type STLs, characterized by the presence of Michael-acceptor structural
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motifs, were demonstrated to be endowed with high-level in vitro activity against Trypanosoma
brucei rhodesiense [55]. In their work, Lenz and colleagues [56] studied the molecular basis of the
activity of different furanoheliangolides. The STL 4,15-iso-atriplicolide tiglate and its homologues
were demonstrated to inhibit trypanothione reductase (TR), an enzyme playing a critical role in
the metabolism and survival of trypanosomatids. The authors also highlighted the structural
requirements necessary for the irreversible TR inactivation by this class of STLs. This study adds a key
piece of information toward the full therapeutic exploitation of STLs in the field of human African
trypanosomiasis and related NTDs.
34. The Pseudomonas aeruginosa Importer PfeA-Fe3+-Enterobactin Complex Indicates New Ways
to Overcome Bacterial Resistance to Antibiotics
Highlighted by Stefano Mangani
Iron is an essential nutrient for bacteria that have evolved siderophore molecules to chelate
Fe3+ ions from insoluble ferric compounds present in the environment. In Gram-negative
bacteria Fe3+-siderophore complexes are recognized by selective outer-membrane TonB-dependent
transporters [57] that bind the complex and translocate it into the periplasmic space. One of the
mechanisms of bacterial resistance to antibiotics are the multidrug efflux pumps [58]. To overcome this
aspect of bacterial resistance, a “Trojan horse” strategy has been conceived, consisting of attaching an
antibiotic molecule to a siderophore [59]. An international research team has recently established the
essential role played by an extracellular recognition site of the PfeA importer of the pathogen
Pseudomonas aeruginosa in binding the Fe3+-enterobactin (a secreted siderophore) complex [60].
The binding of the Fe3+-enterobactin complex to this site is the obligatory event leading to the
import of the siderophore into the bacterium periplasmic space. This study indicates that specifically
designed siderophore-antibiotic complexes, targeting the enterobactin-dependent iron-uptake system of
P. aeruginosa constitutes a promising approach to fight antibiotic resistance by this threatening pathogen.
35. Anticancer Phosphonodiesters Containing Nature Inspired Molecular Scaffolds
Highlighted by Carlo Siciliano
Great efforts are dedicated to the synthesis of new chemotherapeutic drugs with optimal
characteristics, and molecular structures inspired by natural scaffolds, e.g. phenyl moieties, as
found in known powerful antioxidants. A recent work [61] reports on the design of a series of
interesting anticancer candidates, containing a 2,6-diaminopyridine scaffold functionalized with a
phosphonate ester moiety linked to sterically hindered dialkylated phenol rings. The synthesis is very
simple and based on the heteroaromatic electrophilic substitution of the 2,6-diaminopyridine lead
core with aryl 3,5-di-tert-butyl-4-oxocyclohexa-2,5-dienylidene methylphosphonates. All compounds
were extensively tested for their biological activities. Antioxidant, antimicrobial (bacteriostatic and
fungistatic), cytotoxicity, and haemolytic tests were completed by a multiplex analysis on apoptosis
markers, establishing the role of the internal pathway of caspase-9 activation. The natural dialkylated
oxyphenol ring is mandatory for the biological activity. None of the compounds showed antimicrobial
or haemolytic activity, but in vitro tests, using normal Chang liver cells as the reference, highlighted
the high efficiency of all compounds against a variety of tumor cell cultures (breast adenocarcinoma,
epithelioid and human lung carcinoma, human prostate cancer), with a totally negative cytotoxicity.
36. A Bioinspired Technology as an Antitumor Drug Carrier: Enzymatic Self-Assemblies
Highlighted by Stefania Galdiero
The development of amphiphilic peptides, in combination with an enzyme-responsive
self-assembly are of great interest in biomedicine and biotechnology and could lead to nanomaterials
having great potential as vectors for antitumor therapeutics. Gong et al. designed a positively
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charged amphiphilic peptide, A6K2, able to stably self-assemble in nanovesicles, which slowly break
down and gradually form nanofibres following enzyme catalysis [62]. Furthermore, the lipid-soluble
antitumor drug doxorubicin (DOX) could be loaded into the hydrophobic core of the nanovesicles
yielding nanomaterials with outstanding antibacterial and antitumor properties, low cytotoxicity to
normal mammalian cells and excellent selectivity for cancer cells. They developed an innovative
and fascinating approach to attack tumor cells and cause tumor cell death, which suggests that
nanomaterials with great potential in drug delivery for biomedical applications are on their way.
37. MOST: A New Strategy with High Precision to Pry into the Vasculature-Dependent
Pathogenesis of Alzheimer’s Disease
Highlighted by Hong Liu
Mounting evidence reveals that Alzheimer’s disease (AD) progression and severity are highly
associated with the structural and functional integrity of the cerebral vasculature. Efforts have been
made to obtain the 3D atlases of the vasculature for whole-brain samples on a mesoscopic level.
However, high resolution and large sample size are mutually exclusive in conventional imaging
methods. Recently, by using micro-optical sectioning tomography (MOST), a study has successfully
generated cross-scale whole-brain 3D atlases that cover the entire vascular system from large vessels
down to smallest capillaries at submicron resolution [63]. Meanwhile, its characterization of the
hippocampus has demonstrated that it is more susceptible to vasculature dysfunction due to a lower
mean vascular diameter, volume fraction and length density. The study also compared the vasculature
morphology of both wild-type mice and APPsew/PSEN1dE9 transgenic (Tg-AD) mice and discovered
that the reduction of the mean vessel diameter, vascular-volume fraction and average branch angle
leads to poor blood perfusion in the hippocampus of Tg-AD mice. Overall, this study provides a new
insight on vasculature-related AD pathogenesis and a potential therapeutic approach for AD.
38. Accessing New PET Radiotracers with Copper-Mediated Radiofluorination: Radiosynthesis
of [18F]Atorvastatin
Highlighted by Peter J. H. Scott
Positron emission tomography (PET), a functional imaging technique using bioactive molecules
tagged with PET radionuclides such as 18F (radiopharmaceuticals), is increasingly used by
pharmaceutical companies to accelerate drug discovery [64]. PET can provide quantitative information
on target engagement (which can inform dose projection), as well as any off-target binding that
might present safety, toxicity and/or side effect concerns. Historically, use of PET in such applications
has been limited because of difficulties in labeling pharmaceutical assets with 18F. For example,
cholesterol-lowering statins are amongst the biggest-selling drugs worldwide but there are limited
examples of 18F-labeled versions being used to support their development. Recently however,
copper-mediated radiofluorination (CMRF) has greatly expanded the chemical space accessible
for labeling with 18F [65]. Reflecting on this, Elsinga recently employed CMRF to synthesize
[18F]atorvastatin from a pinacol boronate ester (BPin) precursor (Figure 9) [66]. As one of the
most complex substrates labeled with CMRF to date, the work highlights important potentialities and
limitations of CMRF going forward. The team obtained [18F]atorvastatin in ~2% radiochemical yield,
making this important radiopharmaceutical available for researchers in the cholesterol treatment space.
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39. Fighting Hypoxic Tumors with Photoactivated Organometallics
Highlighted by Cristóbal de los Ríos
Photodynamic therapy with metal complexes has recently emerged as an interesting approach to
avoid chemoresistance and side effects in cancer. However, current photoactivated metal complexes
need O2 to exert their action. Thus, they lose activit in cancer cells growing in hypoxic environments,
which is a rather common situation. T solve this problem, an interesting paper has reported the
chem therap utic profile of an iridium complex effective in both hypoxia and normoxia [67]. The key
step is the photocatalytical oxidation of NADH, which is essential for cell proliferation under hyp xia,
so its disru tion lead to cancer c ll death. This iridium complex (Figure 10) was f lly char cterized
by X- y, as well as by its electro and photochemical properties. It presents phosphorescence when
irradiated at 463 nm, and is stable under dark or light conditions. By DFT, the auth rs hypothesize a pi-pi
adduct between NADH and the excited-state Ir complex, facilitating NADH oxidation by one-electron
transfer. Under light irradiation, it noticeably reduced cell viability of several cancer cell lines in both
hypoxia and normoxia. Cisplatin was much less potent in similar cell lines under hypoxia.
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40. Enzymatic Preparation of 2’3’-Cyclic Dinucleotides and Their Binding to STING
Adaptor Protein
Highlighted by Luigi A. Agrofoglio
The cyclic dinucleotide-cGAS–STING axis plays important roles in host immunity, DNA, and
RNA virus-sensing. Cyclic dinucleotides (CDNs) are natural substrates that directly activate STING
signaling. Indeed, numerous synthetic routes for 2’3’- and 3’3’CDNs have been explored but are
suffering from complex and multistep syntheses. Researchers from Czech Republic have investigated
the use of dinucleotide synthases for 2’3’CDN preparation [68]. CDNs are anchored to STING protein
through pi–pi and cation–pi interactions. They have identified the most suitable enzyme for this purpose
and obtained 33 CDNs (modified at the heterocycle moiety), and determined SAR between STING
and CDNs by computational chemistry and QM/MM calculations. These data have great potential to
design small molecules as well as new CDNs able to activate (or not) the cGAS-STING pathway.
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41. Pteridine-Reductase-1 Inhibitors as a New Weapon against Trypanosoma brucei Infections
Highlighted by Simona Collina
Trypanosoma brucei is the causative agent of the neglected human African trypanosomiasis (HAT)
disease. Current drug treatments suffer from host toxicity and emerging resistance. An attractive start
point for discovering new drugs against this neglected disease is targeting enzymes essential for the
parasite. The finding that the pteridine reductase enzyme is essential for parasite survival offers an
opportunity to exploit a known, druggable target for the treatment of HAT.
Landi et al. [69] exploited cycloguanil as a scaffold for the development of novel
pteridine-reductase-1 (PTR1) inhibitors. The elucidation of the binding mode supported the rational
design of novel 2,4-diamino-1,6-dihydrotriazine derivatives, thus identifying two new potent PTR1
inhibitors as a valuable starting point for the development of dual PTR1 and dihydrofolate reductase
(DHFR) inhibitors with antiparasitic activity. The simultaneous inhibition of DHFR and PTR1 in
T. brucei is a promising new strategy for the treatment of HAT and the novel 1,6-dihydrotriazines
represent new molecular tools to develop potent dual PTR1 and DHFR inhibitors. Moreover, the
similarity of the target structures among the different organisms suggests that the triazine core can be
developed further for pan-PTR1-enzyme inhibition.
42. Exploring and Targeting Protein–Protein Druggable Cavities
Highlighted by Rita C. Guedes
There are more than 645,000 reported disease-relevant protein–protein interactions (PPIs) in the
human interactome. However, historically PPIs were regarded as “undruggable” targets, an idea
that was challenged by recent clinical successes and opened a totally new era in drug discovery
research. Today, several PPI modulators are under clinical trials for a broad range of therapeutic
areas, with a special focus in oncology. PPIs are difficult to modulate, especially with small molecules,
since they involve large and flat protein surfaces lacking the deep and well-defined binding pockets,
suitable to bind a ligand with high affinity, found in the “traditional” targets of most currently existing
therapeutic drugs.
Rognan and coworkers [70] developed a fully automated structure-based workflow, to identify
and prioritize druggable cavities. In this work, the entire Protein Data Bank was exploited to identify
PPI interfaces and different types of druggable cavities in protein–ligand complexes, and based on their
properties and spatial locations, classify them (interfacial, rim, allosteric, orthosteric). A systematic
comparison between the pocket cavities identified from the Protein Data Bank protein-complexes and
PPI cavities was performed (http://drugdesign.unistra.fr/ppiome).
43. The Enemy of My Enemy Is My Friend: A New Antibiotic Selective for Gram-Negative
Pathogens Isolated from Nematode Microbiome Symbionts
Highlighted by Diego Muñoz-Torrero
Following the logic that antimicrobial compounds could be found in bacteria that share similar
requirements for antibiotics with humans, the group of Kim Lewis has discovered darobactin, the
first member of a new class of antibiotics that selectively kills Gram-negative bacteria (GNB) [71].
GNB that are common opportunistic pathogens of humans are abundant in the gut microbiome
of entomopathogenic nematodes, where GNB are competitors of nematophilic symbiotic bacteria.
It was reasoned that nematode symbionts could release antimicrobials to defend themselves against
GNB. Upon a screening of a library of nematode symbionts (Photorhabdus and Xenorhabdus strains)
against Escherichia coli, they identified darobactin, a modified heptapeptide with an unusual structure
(Figure 11) and an unusual mode of action on an essential outer membrane protein (BamA). Darobactin
is effective against important GNB in vitro and in several mouse septicemia models, with little or no
Molecules 2020, 25, 119 20 of 24
activity on Gram-positive bacteria, gut commensals, and human cell lines. A good opportunity to
replenish the reduced pipeline of antibiotics against drug-resistant GNB!
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